Skip to main content
SpringerLink
Log in

Dalbavancin/vancomycin

Development of drug resistance: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Werth BJ, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clinical Microbiology and Infection 24: 429.e1-e5, No. 4, Apr 2018. Available from: URL: http://doi.org/10.1016/j.cmi.2017.07.028 - USA

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dalbavancin/vancomycin. Reactions Weekly 1697, 135 (2018). https://doi.org/10.1007/s40278-018-44691-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-44691-9

Search

Navigation